Extracellular Vesicle-Encapsulated miR-183-5p from Rhynchophylline-Treated H9c2 Cells Protect against Methamphetamine-Induced Dependence in Mouse Brain by Targeting NRG1

<div>(a) Particle size distribution of EV nanoparticles. (b) Morphology of EVs observed using transmission electron microscopy (scale: 100 nm). (c) Western blot detection of TSG101 and CD63 proteins of EVs. Con: EVs extracted from cultured nontreated H9c2; Rhy + Meth: EVs extracted from cultured H9c2 treated with 250 <i>μ</i>M Meth for 48 h and 100 <i>μ</i>M Rhy for 24 h; Meth: EVs extracted from cultured H9c2 treated with 250 <i>μ</i>M Meth for 48 h; Rhy: EVs extracted from cultured H9c2 treated with 100 <i>μ</i>M Rhy for 24 h. (d) PKH26-labeled EVs secreted by H9c2 are taken up by neuronal HT22 cells (scale: 10 <i>μ</i>m).</div>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: Extracellular Vesicle-Encapsulated miR-183-5p from Rhynchophylline-Treated H9c2 Cells Protect against Methamphetamine-Induced Dependence in Mouse Brain by Targeting NRG1 

Figure 1 | Extracellular Vesicle-Encapsulated miR-183-5p from Rhynchophylline-Treated H9c2 Cells Protect against Methamphetamine-Induced Dependence in Mouse Brain by Targeting NRG1 